Botanix Quarterly Activities Report and Appendix 4C Q2 FY26
Filed with ASX · · 12 pages · English
Watch Botanix Pharmaceuticals' latest callBotanix Pharmaceuticals (ASX:BOT) Q2 2026 Earnings Call · Replay · Mar 2Read the transcript of Botanix Pharmaceuticals (ASX:BOT) Q2 2026 Earnings CallPhiladelphia PA and Phoenix AZ 27 January 2026: Clinical dermatology company, Botanix Pharmaceuticals Limited (ABN 70 009 109 755) (ASX:BOT, “Botanix” or “the Company”), is pleased to release its Quarterly Activity Report and Appendix 4C Quarterly Cash Flow Report for the period ended 31 December 2025. Key highlights • Total prescriptions shipped grew 24% for the quarter from 20,418 in Q1 FY26 to
Botanix Pharmaceuticals Limited on 6ix
Story so far
Earlier from Botanix Pharmaceuticals
- Botanix Quarterly Activities Report and Appendix 4C Q1 FY26
- Appendix 4E & Annual Report for the Year Ended 30 June 2025
- Response to ASX Aware Letter
- June 2025 Quarterly Activities Report and Appendix 4C
- Botanix Provides Sofdra Launch Update
Later from Botanix Pharmaceuticals
- Pause in Trading
- Trading Halt
- Botanix Receives Capital Raise Commitments of A$45 Million
- Appendix 4D and Half Year Report
- S&P DJI Announces March 2026 Quarterly Rebalance
Follow Botanix Pharmaceuticals into a list and get an email when it puts out news.
Follow Botanix Pharmaceuticals